Investopedia on MSN6d
PayPal Stock Tumbles on Lower-Than-Expected Adjusted EarningsShares of PayPal slumped Tuesday as the payment platform's adjusted earnings missed estimates for the final quarter of 2024.
NEW YORK — NEW YORK — Ares Capital Corp. (ARCC) on Wednesday reported fourth-quarter earnings of $357 million. On a per-share basis, the New York-based company said it had net income of 55 cents.
Earnings per share came in at $1.09, which slightly beat analysts’ consensus estimate of $1.08. In addition, sales increased by 24.2% year-over-year, with revenue hitting $7.7 billion.
The company forecasts third-quarter non-GAAP earnings per share between 56 cents and 58 cents. The consensus mark for earnings is pegged at 51 cents per share, implying a rise of 24.39% from the ...
Ares Capital reported Q4 earnings on Feb. 5, which highlighted leadership changes, solid financials, and a record net asset ...
Major indices on the Wall Street were little changed on Friday as investors tried to make sense of the latest job figures and ...
For the most recent quarter, Marvell was expected to post earnings of $0.40 per share, but it reported $0.43 per share instead, representing a surprise of 7.50%. For the previous quarter ...
Qualys anticipates non-GAAP earnings per share between $1.28 and $1.38. The consensus mark for fourth-quarter earnings has remained unchanged at $1.35 per share over the past 60 days, suggesting a ...
Bank of America (BAC) is forecasting revenue of $187.24 billion, about $1.53 per share, for the fourth quarter ... reflecting investing optimism ahead of the earnings report.
The tech giant reported net sales of $187.79 billion, compared to estimates of $187.32 billion, while earnings per share came in at $1.86, compared to $1.50. Sales in its key Amazon Web Services ...
Its earnings per share (EPS) rose nearly fourfold from the year-ago period to $3.21, largely due to a tax valuation release. "Uber ended 2024 with our strongest quarter ever, as growth accelerated ...
CNBC on MSN6d
Pfizer tops earnings estimates as Covid product sales beat expectations and cost cuts pay offThe results cap off a critical year for Pfizer, which has been slashing costs as it recovers from the rapid decline of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results